Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial

Mark B. Zimering, Robert J. Anderson, Thomas E. Moritz, Ling Ge

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen that does not normally circulate, but increases in microalbuminuric adult type 2 diabetes mellitus. Earlier work indicated an unexpected association between low levels of plasma bFGF immunoreactivity and the subsequent 4-year need for laser treatment in 172 patients from the Veterans Affairs Diabetes Trial (mean: age, 59 years; diabetes duration, 11 years; baseline hemoglobin A1c, 9.5%). In the present study, we tested for an association between endothelial cell inhibitory autoantibodies in plasma and the need for laser treatment. Inhibitory activity in endothelial cells from the immunoglobulin G fractions of plasma was significantly associated (P = .002) with low plasma bFGF immunoreactivity. There was a significant association (P = .003) between endothelial cell inhibitory autoantibodies in baseline plasma and the time to occurrence of first laser treatment after 4 years of study treatment. After adjusting for other risk factors, endothelial cell inhibitory activity greater than 90% vs less than or equal to 90% (hazard ratio, 0.2; P = .003) and low-density lipoprotein cholesterol concentration (hazard ratio, 0.98; P = .02) were each significant predictors of the time to first postrandomization laser occurrence. These results suggest that circulating autoantibodies inhibitory in endothelial cells may contribute to the need for laser treatment in adult men with advanced type 2 diabetes mellitus. Among the possible risk factors evaluated, baseline insulin use was the only variable significantly inversely (P = .02) associated with the baseline occurrence of inhibitory endothelial cell autoantibodies. It could not be determined whether insulin use may decrease the occurrence of endothelial cell inhibitory autoantibodies in advancing adult type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)882-887
Number of pages6
JournalMetabolism: Clinical and Experimental
Volume58
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Light Coagulation
Veterans
Autoantibodies
Lasers
Endothelial Cells
Fibroblast Growth Factor 2
Type 2 Diabetes Mellitus
Insulin
Therapeutics
Mitogens
LDL Cholesterol
Hemoglobins
Immunoglobulin G

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. / Zimering, Mark B.; Anderson, Robert J.; Moritz, Thomas E.; Ge, Ling.

In: Metabolism: Clinical and Experimental, Vol. 58, No. 6, 06.2009, p. 882-887.

Research output: Contribution to journalArticle

@article{7ef85178f1d44449886536e9b3fd4533,
title = "Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial",
abstract = "Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen that does not normally circulate, but increases in microalbuminuric adult type 2 diabetes mellitus. Earlier work indicated an unexpected association between low levels of plasma bFGF immunoreactivity and the subsequent 4-year need for laser treatment in 172 patients from the Veterans Affairs Diabetes Trial (mean: age, 59 years; diabetes duration, 11 years; baseline hemoglobin A1c, 9.5{\%}). In the present study, we tested for an association between endothelial cell inhibitory autoantibodies in plasma and the need for laser treatment. Inhibitory activity in endothelial cells from the immunoglobulin G fractions of plasma was significantly associated (P = .002) with low plasma bFGF immunoreactivity. There was a significant association (P = .003) between endothelial cell inhibitory autoantibodies in baseline plasma and the time to occurrence of first laser treatment after 4 years of study treatment. After adjusting for other risk factors, endothelial cell inhibitory activity greater than 90{\%} vs less than or equal to 90{\%} (hazard ratio, 0.2; P = .003) and low-density lipoprotein cholesterol concentration (hazard ratio, 0.98; P = .02) were each significant predictors of the time to first postrandomization laser occurrence. These results suggest that circulating autoantibodies inhibitory in endothelial cells may contribute to the need for laser treatment in adult men with advanced type 2 diabetes mellitus. Among the possible risk factors evaluated, baseline insulin use was the only variable significantly inversely (P = .02) associated with the baseline occurrence of inhibitory endothelial cell autoantibodies. It could not be determined whether insulin use may decrease the occurrence of endothelial cell inhibitory autoantibodies in advancing adult type 2 diabetes mellitus.",
author = "Zimering, {Mark B.} and Anderson, {Robert J.} and Moritz, {Thomas E.} and Ling Ge",
year = "2009",
month = "6",
doi = "10.1016/j.metabol.2009.02.023",
language = "English",
volume = "58",
pages = "882--887",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial

AU - Zimering, Mark B.

AU - Anderson, Robert J.

AU - Moritz, Thomas E.

AU - Ge, Ling

PY - 2009/6

Y1 - 2009/6

N2 - Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen that does not normally circulate, but increases in microalbuminuric adult type 2 diabetes mellitus. Earlier work indicated an unexpected association between low levels of plasma bFGF immunoreactivity and the subsequent 4-year need for laser treatment in 172 patients from the Veterans Affairs Diabetes Trial (mean: age, 59 years; diabetes duration, 11 years; baseline hemoglobin A1c, 9.5%). In the present study, we tested for an association between endothelial cell inhibitory autoantibodies in plasma and the need for laser treatment. Inhibitory activity in endothelial cells from the immunoglobulin G fractions of plasma was significantly associated (P = .002) with low plasma bFGF immunoreactivity. There was a significant association (P = .003) between endothelial cell inhibitory autoantibodies in baseline plasma and the time to occurrence of first laser treatment after 4 years of study treatment. After adjusting for other risk factors, endothelial cell inhibitory activity greater than 90% vs less than or equal to 90% (hazard ratio, 0.2; P = .003) and low-density lipoprotein cholesterol concentration (hazard ratio, 0.98; P = .02) were each significant predictors of the time to first postrandomization laser occurrence. These results suggest that circulating autoantibodies inhibitory in endothelial cells may contribute to the need for laser treatment in adult men with advanced type 2 diabetes mellitus. Among the possible risk factors evaluated, baseline insulin use was the only variable significantly inversely (P = .02) associated with the baseline occurrence of inhibitory endothelial cell autoantibodies. It could not be determined whether insulin use may decrease the occurrence of endothelial cell inhibitory autoantibodies in advancing adult type 2 diabetes mellitus.

AB - Basic fibroblast growth factor (bFGF) is a potent endothelial cell mitogen that does not normally circulate, but increases in microalbuminuric adult type 2 diabetes mellitus. Earlier work indicated an unexpected association between low levels of plasma bFGF immunoreactivity and the subsequent 4-year need for laser treatment in 172 patients from the Veterans Affairs Diabetes Trial (mean: age, 59 years; diabetes duration, 11 years; baseline hemoglobin A1c, 9.5%). In the present study, we tested for an association between endothelial cell inhibitory autoantibodies in plasma and the need for laser treatment. Inhibitory activity in endothelial cells from the immunoglobulin G fractions of plasma was significantly associated (P = .002) with low plasma bFGF immunoreactivity. There was a significant association (P = .003) between endothelial cell inhibitory autoantibodies in baseline plasma and the time to occurrence of first laser treatment after 4 years of study treatment. After adjusting for other risk factors, endothelial cell inhibitory activity greater than 90% vs less than or equal to 90% (hazard ratio, 0.2; P = .003) and low-density lipoprotein cholesterol concentration (hazard ratio, 0.98; P = .02) were each significant predictors of the time to first postrandomization laser occurrence. These results suggest that circulating autoantibodies inhibitory in endothelial cells may contribute to the need for laser treatment in adult men with advanced type 2 diabetes mellitus. Among the possible risk factors evaluated, baseline insulin use was the only variable significantly inversely (P = .02) associated with the baseline occurrence of inhibitory endothelial cell autoantibodies. It could not be determined whether insulin use may decrease the occurrence of endothelial cell inhibitory autoantibodies in advancing adult type 2 diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=65549099572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549099572&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2009.02.023

DO - 10.1016/j.metabol.2009.02.023

M3 - Article

C2 - 19375761

AN - SCOPUS:65549099572

VL - 58

SP - 882

EP - 887

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 6

ER -